Regeneron Pharmaceuticals Inc. (REGN) Rating Reiterated by Roth Capital
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)‘s stock had its “buy” rating reissued by analysts at Roth Capital in a report released on Wednesday. They presently have a $520.00 price objective on the biopharmaceutical company’s stock. Roth Capital’s price target would suggest a potential upside of 34.70% from the company’s previous close.
Several other research firms also recently issued reports on REGN. Robert W. Baird reaffirmed a “neutral” rating and set a $448.00 price target on shares of Regeneron Pharmaceuticals in a research note on Friday, September 23rd. Goldman Sachs Group Inc. reiterated a “buy” rating and set a $521.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 27th. Vetr cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $419.76 price objective for the company. in a research report on Monday, July 11th. Sanford C. Bernstein reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Thursday, June 30th. Finally, Zacks Investment Research cut shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 4th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Regeneron Pharmaceuticals has an average rating of “Hold” and a consensus target price of $480.09.
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 3.31% during midday trading on Wednesday, reaching $373.26. 524,585 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 12 month low of $329.09 and a 12 month high of $592.59. The stock has a 50 day moving average of $400.58 and a 200-day moving average of $392.25. The stock has a market cap of $39.06 billion, a P/E ratio of 58.23 and a beta of 1.31.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/regeneron-pharmaceuticals-inc-regn-rating-reiterated-by-roth-capital-3.html
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $2.82 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.65 by $0.17. The firm earned $1.21 billion during the quarter, compared to the consensus estimate of $1.24 billion. Regeneron Pharmaceuticals had a net margin of 15.65% and a return on equity of 23.77%. The company’s revenue for the quarter was up 21.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.89 earnings per share. On average, equities research analysts forecast that Regeneron Pharmaceuticals will post $11.02 EPS for the current fiscal year.
In related news, Director Joseph L. Goldstein sold 2,125 shares of the business’s stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $425.00, for a total transaction of $903,125.00. Following the completion of the transaction, the director now owns 15,125 shares of the company’s stock, valued at $6,428,125. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 10.40% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. IFP Advisors Inc boosted its position in Regeneron Pharmaceuticals by 32.3% in the second quarter. IFP Advisors Inc now owns 328 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 80 shares in the last quarter. Advisory Services Network LLC boosted its position in Regeneron Pharmaceuticals by 5,433.3% in the second quarter. Advisory Services Network LLC now owns 332 shares of the biopharmaceutical company’s stock worth $116,000 after buying an additional 326 shares in the last quarter. Fuller & Thaler Asset Management Inc. bought a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $140,000. Brave Asset Management Inc bought a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $157,000. Finally, Bessemer Group Inc. boosted its position in Regeneron Pharmaceuticals by 45.4% in the first quarter. Bessemer Group Inc. now owns 548 shares of the biopharmaceutical company’s stock worth $198,000 after buying an additional 171 shares in the last quarter. 68.16% of the stock is owned by institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company’s segment includes activities related to the discovery, development and commercialization of pharmaceutical products for the treatment of serious medical conditions.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.